News >

Ramucirumab Improves PFS in Phase III Urothelial Carcinoma Trial

Jason Harris
Published: Wednesday, May 31, 2017

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD

Adding ramucirumab (Cyramza) to docetaxel led to a statistically significant improvement in progression-free survival (PFS) versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma, according to results from the phase III RANGE trial.

Patients in arm B underwent a median of 4.5 cycles of docetaxel, compared with 3.0 for arm A and 2.0 for arm C. Similarly, more patients completed at least 6 cycles of treatment in arm B (41%) compared with arm A (22%) and arm C (27%). Median relative dose-intensities for docetaxel were 99% (IQR, 90%-100%) for arm A, 100% (IQR, 89%-101%) for arm B, and 99% (IQR, 91%-100%) for arm C.
Petrylak DP, Tagawa ST, Kohli M, et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase ii trial. J Clin Oncol. 2016;34(13):1500-1509.doi: 10.1200/JCO.2015.65.0218.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x